carrito Compra

(0 Productos)

Gastos de envío GRATIS

Solo para España


THE ESC TEXTBOOK OF HEART FAILURE

THE ESC TEXTBOOK OF HEART FAILURE-9780198891628
  1. Autor:

    Seferovic

  2. Isbn:

    9780198891628

  3. Páginas:

    1040

  4. Año:

    2024

  5. Edición:

    1

  6. Idioma:

    Ingles

  7. Disponibilidad:

    En Stock

Precio s/iva:

206.73 €

196,39  €
Volver

DESCRIPTION:
The ESC Textbook of Heart Failure is the latest addition to the European Society of Cardiology (ESC) publications portfolio and is fully supported by the European Heart Failure Association.

The textbook brings together internationally renowned experts in the field of heart failure to present an up-to-date understanding of all aspects of this chronic condition that worsens with time. It is estimated that the worldwide population of patients suffering from heart failure is approximately 26 million. This clinically oriented work reflects contemporary European guidelines from the ESC and the European Heart Failure Association and summarizes the latest evidence from clinical trials.

Made up of eighteen different sections the textbook covers the epidemiology, etiology, prevention, pathophysiology, and clinical phenotypes of heart failure. The assessment and management of chronic, acute, and advance heart failure are all discussed in detail. As well as chapters dedicated to self-care and patient education, the multidisciplinary approach to heart failure management, and clinical trial design and interpretation. The future direction of the field is discussed throughout with separate chapters on digital health, big data, and telemedicine/remote monitoring in heart failure also included.

A must read for cardiovascular healthcare specialists in Europe and across the world it should also appeal to those in training, general physicians and those caring of the elderly, cardiothoracic surgeons, primary care doctors, and specialist nurses too.

CONTENTS:
Section 1: Universal definition of heart failure
1.1:Universal definition of heart failure
Section 2: Epidemiology of heart failure
2.1:Epidemiology of heart failure
Section 3: Etiology of heart failure
3.1:Coronary artery disease
3.2:Hypertension
3.3:Valvular heart disease
3.4.1:Genetic basis of cardiomyopathies
3.4.2:Dilated and hypokinetic non-dilated cardiomyopathy
3.4.3:Hypertrophic cardiomyopathy
3.4.4:Restrictive cardiomyopathy
3.4.5:Arrhythmogenic right ventricular cardiomyopathy
3.4.6:Peripartum cardiomyopathy
3.4.7:Takotsubo cardiomyopathy
3.5:Myocarditis and pericarditis
3.6:Congenital heart disease
3.7:Endocrine and metabolic disorders
3.8:Obesity
3.9:Cancer and cancer therapy
3.10:Toxins (e.g. alcohol etc.) and infections
Section 4: Prevention of heart failure
4.1:Prevention of heart failure
Section 5: Pathophysiology of heart failure
5.1:Molecular and cellular mechanisms
5.2:Alterations in myocardial metabolism
5.3:Ventricular remodelling
5.4:Neurohormonal activation
5.5:Immune-mediated mechanisms
5.6:Inflammation, oxidative stress and endothelial dysfunction
5.7:Alterations in peripheral circulation and renal function, Alterations in peripheral circulation and renal function
5.8:Systemic adaptations in metabolism and nutritive status
Section 6: Clinical phenotypes of chronic heart failure
6.1:HFrEF
6.2:HFmrEF
6.3:HFpEF
6.4:Right heart failure
Section 7: Chronic heart failure: diagnostic and prognostic assessment
7.1:Clinical assessment
7.2:Biomarkers in diagnostic and prognostic assessment
7.3:Echocardiography
7.4:Nuclear medicine
7.5:Cardiac computed tomography
7.6:Cardiac magnetic resonance
7.7:Cardiopulmonary exercise
7.8:Cardiac catheterization, invasive imaging and haemodynamic assessment
Section 8: Chronic heart failure: pharmacological management
8.1:Angiotensin converting enzyme inhibitors
8.2:Angiotensin I receptor blockers
8.3:ARNI
8.4:Beta-blockers
8.5:Mineralocorticoid receptor agonists
8.6:Ivabradine
8.7:Vasodilators
8.8:Digitalis glycosides
8.9:Diuretics
8.10:Inotropes and inodilators
8.11:SGLT2 inhibitors
8.12:Ancillary pharmacological treatment options
8.13:New and emerging therapies
Section 9: Chronic heart failure: non-pharmacological management
9.1:Implantable cardioverter defibrillator
9.2:Cardiac resynchronization therapy
9.3:Cardiac surgery
9.4:Valve interventions
9.5:Ancillary procedures
9.6:Cardiac rehabilitation
Section 10: Acute heart failure
10.1:Acute heart failure: diagnostic and prognostic assessment
10.2:Acute heart failure: management
Section 11: Advanced heart failure
11.1:Advanced heart failure: assessment
11.2:Advanced heart failure: management
11.3:Mechanical circulatory support
11.4:Heart transplantation
11.5:Palliative care and end-of-life management
Section 12: Comorbidities and clinical conditions
12.1:Chronic kidney disease: Clinical Aspects of Chronic Kidney Disease in Heart Failure
12.2:Dyskalaemia
12.3:Chronic lung disease
12.4:Ventilatory Abnormalities and Sleep Disordered Breathing
12.5:Pulmonary hypertension
12.6:Cardiac rhythm disorders
12.7:Management of atrial fibrillation in heart failure
12.8:Diabetes, metabolic syndrome and endocrine disorders
12.9:Systemic immune medicated diseases
12.10:Liver and gut dysfunction
12.11:Anaemia and iron deficiency
12.12:Depression and cognitive impairment
12.13:Cancer
12.14:Pregnancy
12.15:Frailty
Section 13: Self-care and patient education
13.1:Self-care and patient education
Section 14: Multidisciplinary approach to heart failure management
14.1:Multidisciplinary approach to heart failure management
Section 15: Clinical trial design and interpretation
15.1:Clinical trial design and interpretation
Section 16: Digital health in heart failure
16.1:Digital health in heart failure
Section 17: Big data in heart failure
17.1:Big data in heart failure
Section 18: Telemedicine and remote monitoring
18.1:Telemedicine and remote monitoring



Libreria Médica Berri 2024 ®